Mitragynine reduces symptoms of alcohol use disorder (and tinnitus) in a self-medication of rodents

Alcohol use disorder (AUD) is a major psychiatric disease. Available pharmacotherapies show rather modest compliance and efficacy. Tinnitus is a highly aversive hearing problem, that may arise from the same unsolved problems as AUD. Based on a patient report of Kratom, a Southeast Asian plant preparation, efficacy in the self-medication of AUD and tinnitus, we tested the main active Kratom alkaloid, mitragynine, for its therapeutic action in AUD mouse models covering various symptoms of the disease. We found that experimenter administered mitragynine (i.p.) inhibits well-established ongoing alcohol consumption in a social setting when alcohol is permanently available. Mitragynine also inhibits alcohol consumption in a non-social, isolated setting. While mitragynine did not work for prophylaxis during abstinence, it markedly attenuated the relapse to binge drinking with alcohol availability restricted to a limited time. Furthermore, mitragynine reduced alcohol seeking behaviour during its establishment as well as during retrieval from memory. It was also effective to attenuate its re-establishment after extinction. We found significant antidepressive effects of mitragynine, during alcohol withdrawal. To address the compliance problem for pharmacotherapies, we established a test that can monitor this and found that mice after a short training, learned to orally self-administer mitragynine hydrochloride leading to a strong reduction in voluntary alcohol drinking. In parallel, mitragynine reduced tinnitus after a noise trauma in a gerbil model. Together, these findings suggest that mitragynine may be used as a pharmacotherapy for AUD and tinnitus with an expected high compliance rate.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.19.767795
Primary Topic
Alkaloids: synthesis and pharmacology
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Mitragynine reduces symptoms of alcohol use disorder (and tinnitus) in a self-medication of rodents

Kasia Radwańska, Zurina Hassan, Renato Frischknecht, Markus R. Heinrich et al.
bioRxiv (Cold Spring Harbor Laboratory)
Alkaloids: synthesis and pharmacology
preprint

Mitragynine reduces symptoms of alcohol use disorder (and tinnitus) in a self-medication of rodents

Kasia Radwańska, Zurina Hassan, Renato Frischknecht, Markus R. Heinrich, Anna Fejtová, Konstantin Tziridis, Nassri Abdoush, Liubov S. Kalinichenko, Johannes Kornhuber, Laura Emrich, Marie-Lou Boyer, Fabian Graßl, Holger Schulze, Gian-Marco Kersten, Christian P. Mueller, Salvador Kirmsse, Nelson Chear Jeng Yeou, Lisa Perschler, Lydia Scheidig, Lissy Windhoesel, Bernadette Hoermann, Martin Strotmann, Darshan Singh, Anna Glotz, Natasha Foerst, Melissa Kienberger
preprint en

Abstract

Alcohol use disorder (AUD) is a major psychiatric disease. Available pharmacotherapies show rather modest compliance and efficacy. Tinnitus is a highly aversive hearing problem, that may arise from the same unsolved problems as AUD. Based on a patient report of Kratom, a Southeast Asian plant preparation, efficacy in the self-medication of AUD and tinnitus, we tested the main active Kratom alkaloid, mitragynine, for its therapeutic action in AUD mouse models covering various symptoms of the disease. We found that experimenter administered mitragynine (i.p.) inhibits well-established ongoing alcohol consumption in a social setting when alcohol is permanently available. Mitragynine also inhibits alcohol consumption in a non-social, isolated setting. While mitragynine did not work for prophylaxis during abstinence, it markedly attenuated the relapse to binge drinking with alcohol availability restricted to a limited time. Furthermore, mitragynine reduced alcohol seeking behaviour during its establishment as well as during retrieval from memory. It was also effective to attenuate its re-establishment after extinction. We found significant antidepressive effects of mitragynine, during alcohol withdrawal. To address the compliance problem for pharmacotherapies, we established a test that can monitor this and found that mice after a short training, learned to orally self-administer mitragynine hydrochloride leading to a strong reduction in voluntary alcohol drinking. In parallel, mitragynine reduced tinnitus after a noise trauma in a gerbil model. Together, these findings suggest that mitragynine may be used as a pharmacotherapy for AUD and tinnitus with an expected high compliance rate.

bioRxiv (Cold Spring Harbor Laboratory)
Universiti Sains Malaysia (MY), Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Alkaloids: synthesis and pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon